Epidemiology

You have full text access to this OnlineOpen article

Reproductive risk factors for incident bladder cancer: Iowa Women's Health Study

  1. Anna E. Prizment,
  2. Kristin E. Anderson,
  3. Bernard L. Harlow,
  4. Aaron R. Folsom†,*

Article first published online: 27 NOV 2006

DOI: 10.1002/ijc.22418

Issue

International Journal of Cancer

International Journal of Cancer

Volume 120, Issue 5, pages 1093–1098, 1 March 2007

Additional Information

How to Cite

Prizment, A. E., Anderson, K. E., Harlow, B. L. and Folsom, A. R. (2007), Reproductive risk factors for incident bladder cancer: Iowa Women's Health Study. Int. J. Cancer, 120: 1093–1098. doi: 10.1002/ijc.22418

Author Information

  1. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN

  1. †

    Fax: +612-624-0315.

*Division of Epidemiology and Community Health, 1300 2nd Street South, Suite 300, University of Minnesota, Minneapolis, MN 55454-1015, USA

Publication History

  1. Issue published online: 19 JAN 2007
  2. Article first published online: 27 NOV 2006
  3. Manuscript Accepted: 26 SEP 2006
  4. Manuscript Received: 7 SEP 2006

Funded by

  • National Cancer Institute. Grant Number: R01 CA39742

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (87K)

References

  • 1
    RiesLAG, HarkinsD, KrapchoM, MariottoA, MillerBA, FeuerEJ, CleggL, EisnerMP, HornerMJ, HowladerN, HayatM, HankeyBF, et al. (eds). SEER cancer statistics review, 1975–2003. Bethesda, MD: National Cancer Institute, 2005. http://seer.cancer.gov/csr/1975_2003/ (accessed July 6, 2006).
  • 2
    Silverman DT, Morrison AS, Devesa SS. Bladder cancer. In: SchottenfeldD, FraumeniJF,Jr, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996; 1156–79.
  • 3
    Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, Fraumeni JF,Jr. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990; 82: 1636–40.
  • 4
    Makela S, Strauss L, Kuiper G, Valve E, Salmi S, Santti R, Gustafsson JA. Differential expression of estrogen receptors α and β in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol 2000; 170: 219–29.
  • 5
    Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int 2000; 86: 32–8.
    Direct Link:
  • 6
    Noronha RF, Rao BR. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 1986; 28: 401–3.
  • 7
    Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 2002; 41: 342–5.
  • 8
    Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, Sonpavde G, Ayala GE, Younes M, Lerner SP. Expression of estrogen receptors-α and -β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006; 106: 2610–16.
    Direct Link:
  • 9
    Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Urol Res 1975; 3: 73–7.
  • 10
    Tanahashi NK, Suzawa N, Azuma C. Effects of sex hormones on oncogenesis in rat urinary bladder by N-butyl-N-(4-hydroxybutyl)- nitrosamine. Int J Clin Pharmacol Biopharm 1977; 15: 101–5.
  • 11
    Reid LM, Leav I, Kwan PW, Russell P, Merk FB. Characterization of a human sex-steroid-responsive transplantable cell carcinoma maintained as a tumor line (R 198) in athymic nude mice. Cancer Res 1984; 44: 4560–73.
  • 12
    Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanism of androgen in bladder carcinogenesis in male rats. Eur Urol 1997; 31: 360–4.
  • 13
    McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006; 163: 236–44.
  • 14
    Cantor KP, Lynch CF, Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 1992; 3: 57–62.
  • 15
    Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S. Smoking and other risk factors for bladder cancer in women. Prev Med 2002; 35: 114–20.
  • 16
    Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vechhia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105: 408–12.
    Direct Link:
  • 17
    Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen–progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327–32.
    Direct Link:
  • 18
    La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. Int J Cancer 1993; 53: 215–19.
    Direct Link:
  • 19
    Miller AB, Barclay TH, Choi NW, Grace MG, Wall C, Plante M, Howe GR, Cinader B, Davis FG. A study of cancer, parity and age at first pregnancy. J Chronic Dis 1980; 33: 595–605.
  • 20
    Bisgard KM, Folsom AR, Hong CP, Sellers TA. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 1994; 139: 990–1000.
  • 21
    Cramer DW, Xu H. Predicting age at menopause. Maturitas 1996; 23: 319–26.
  • 22
    Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004; 15: 100–4.
  • 23
    Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP, Sellers TA, Lazovich D, Prineas RJ. Associations of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women's Health Study. Arch Intern Med 2000; 160: 2117–28.
  • 24
    Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women's Health Study. Cancer 2002; 95: 2316–23.
    Direct Link:
  • 25
    Bromberger JT, Matthews KA, Kuller LH, Wing RR, Neilahn EN, Plantinga P. Prospective study of the determinants of age at menopause. Am J Epidemiol 1997; 145: 124–33.
  • 26
    Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas 2000; 35: 3–9.
  • 27
    Willett W, Stampfer MJ, Bain C, Lipnick R, Speizer FE, Rosner B, Cramer D, Hennekens CH. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983; 117: 651–8.
  • 28
    Salmi S, Santti R, Gustafsson JA, Makela S. Co-localization of androgen receptor with estrogen receptor β in the lower urinary tract of the male rat. J Urol 2001; 166: 674–7.
  • 29
    Laor E, Schiffman ZJ, Braunstein JD, Reid RE, Tolia BM, Koss LG, Freed SZ. Androgen receptors in bladder tumors. Urology 1985; 25: 161–3.
  • 30
    Croft RP, Lathrop SL, Feddersen RM, Joste NE. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma. Arch Pathol Lab Med 2005; 129: 194–9.
  • 31
    Kaufmann O, Baume H, Dietel M. Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. J Pathol 1998; 186: 165–8.
    Direct Link:
  • 32
    Kim HT, Kim BC, Kim IY, Mamura M, Seong do H, Jang JJ, Kim SJ. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem 2002; 277: 32510–15.
  • 33
    Pu YS, Hsieh TS, Tsai TC, Cheng AL, Hsieh CY, Su IJ, Lai MK. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 1995; 154: 601–5.
  • 34
    Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 2001; 21: 711–15.
  • 35
    Hextall A. Oestrogens and lower urinary tract function. Maturitas 2000; 36: 83–92.
  • 36
    Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology 2003; 62: 45–51.
  • 37
    Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF,Jr. Urinary tract infection and risk of bladder cancer. Am J Epidemiol 1984; 119: 510–15.
  • 38
    La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Franceschi S. Genital and urinary tract diseases and bladder cancer. Cancer Res 1991; 51: 629–31.
  • 39
    Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 2006; 3: 327–40.
  • 40
    Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer E. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987; 126: 319–25.
  • 41
    Den Tonkelaar I. Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. Maturitas 1997; 27: 117–23.
  • 42
    McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996; 143: 1195–1202.
  • 43
    Sellers TA, Kushi LH, Potter JD, Kaye SA, Nelson CL, McGovern PG, Folsom AR. Effect of family history, body fat distribution, and reproductive factors on risk of postmenopausal breast cancer. N Engl J Med 1992; 326: 1323–9.
  • 44
    Vachon CM, Mink PJ, Janney CA, Sellers TA, Cerhan JR, Hartmann L, Folsom AR. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology 2002; 13: 66–71.
View Full Article (HTML) Get PDF (87K)